Before revision: Bamlanivimab/etesevimab Bebtelovimab Casirivimab/imdevimab Regdanvimab Sotrovimab Tixagevimab/cilgavimab Vilobelimab Novel viral replication inhibitors Molnupiravir Novel protease inhibitors Ensitrelvir Nirmatrelvir/ritonavir Other Sabizabulin Planning and coordination Early planning Over 2018–20, new initiatives to stimulate vaccine and antiviral drug development included partnerships between governmental organizations and industry, such as the European Innovative Medicines Initiative, the US Critical Path Initiative to enhance innovation of drug development, and the Breakthrough Therapy designation to expedite development and regulatory review of promising candidate drugs.
After revision: PemivibartBamlanivimab/etesevimab Bebtelovimab Casirivimab/imdevimab Regdanvimab Sotrovimab Tixagevimab/cilgavimab Vilobelimab Novel viral replication inhibitors Molnupiravir Novel protease inhibitors Ensitrelvir Nirmatrelvir/ritonavir Other Sabizabulin Planning and coordination Early planning Over 2018–20, new initiatives to stimulate vaccine and antiviral drug development included partnerships between governmental organizations and industry, such as the European Innovative Medicines Initiative, the US Critical Path Initiative to enhance innovation of drug development, and the Breakthrough Therapy designation to expedite development and regulatory review of promising candidate drugs.